Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Interleukin-12 Subunit p35 × 90 days × Clear all
NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01468896 2026-04-29

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡